Oyster Point Pharma, Inc.
CIK 0001720725
Revenue (TTM)
$12.99M
Q3 Nov 2022
Net Income (TTM)
−$152.25M
−352.8% YoY
Q3 Nov 2022
EPS Diluted (TTM)
−$5.72
−32.5% YoY
Q3 Nov 2022
Gross Margin
76.9%
Q3 Nov 2022
Operating Margin
-1,049.3%
Q3 Nov 2022
Net Margin
-1,172.2%
Q3 Nov 2022
Free Cash Flow (TTM)
−$80.6M
Q3 Nov 2022
Cash
$68.8M
Q3 Nov 2022
Total Debt
$92.22M
Q3 Nov 2022
Shares Outstanding
26.84M sh
Q3 Nov 2022
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.